Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01324479 · ClinicalTrials.gov registry record · Phase 1
Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 1
- Development phase
- 131
- Enrollment target
NCT01324479 is a Phase 1 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 131 participants.
The verdict
NCT01324479, a Phase 1 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 131 participants
- Enrollment target
Study Summary
This study will assess the safety and efficacy of INC280 in patients with solid tumors that are refractory to current treatment or for which there is not a current standard of care and whose tumors have dysregulation of the c-MET pathway.
Interventions
- DRUG INC280
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 131 participants |
| Start Date | 2012-02-29 |
| Est. Completion | 2017-07-04 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01324479
The ClinicalTrials.gov registry entry for NCT01324479 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 131 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which INC280 is the first listed.
NCT01324479 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01324479 about?
NCT01324479 is a clinical study titled "Study of INC280 in Patients With c-MET Dependent Advanced Solid Tumors". This study will assess the safety and efficacy of INC280 in patients with solid tumors that are refractory to current treatment or for which there is not a current standard of care and whose tumors have dysregulation of the c-MET pathway.
What is the current status of trial NCT01324479?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 131 participants. The study started on 2012-02-29. Estimated completion is 2017-07-04.
What interventions are being tested in trial NCT01324479?
The interventions under investigation include: INC280 (DRUG).
Who is sponsoring clinical trial NCT01324479?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.